NO20044041L - Okso-azabisykliske forbindelser - Google Patents

Okso-azabisykliske forbindelser

Info

Publication number
NO20044041L
NO20044041L NO20044041A NO20044041A NO20044041L NO 20044041 L NO20044041 L NO 20044041L NO 20044041 A NO20044041 A NO 20044041A NO 20044041 A NO20044041 A NO 20044041A NO 20044041 L NO20044041 L NO 20044041L
Authority
NO
Norway
Prior art keywords
integer
formula
group
nalkyl
rer
Prior art date
Application number
NO20044041A
Other languages
English (en)
Inventor
Catherine Kostlan
Bernard Gaudilliere
Henry Jacobelli
Jack Li
Wen-Song Yue
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20044041L publication Critical patent/NO20044041L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Forbindelse valgt fra slike med formel (I) hvori: X,, Xog Xrepresenterer ftxtef^-CRi hvilken Ra er som beskrevet i beskrivelsen, Gi representerer en gnjjj§4g|^ fra slike ifølge formlene (i/a) og (i/b) i hvilke R, Rs og Rer som definert i'" """"" beskrivelsen, G2 representerer en gruppe valgt fra karbon-karbon trippelbinding, - CH=C=CH-, C=0, C=S, S(0)i hvilke n1 representerer et helt tall fra 0 til og med 2, eller en gruppe ifølge formelen (i/c) i hvilken Yrepresenterer O, S, -NH eller. -Nalkyl, og Yrepresenterer O, S, -NH eller -Nalkyl, ri er et helt tall fra 0 til og med 6, og m er et helt tall f ra 0 til og med 7, Zrepresenterer -CRgR, hvori Rg og Rer som definert i beskrivelsen, A representerer et ringsystem, Ri representerer en gruppe valgt fra H, alkyl, alkenyl, alkynyl, eventuelt substituert og gruppen med formel (i/d) i hvilken p, Z, B, q og Ger som definert i beskrivelsen og eventuelt, dens optiske isomerer, N-oksyd, og addisjonssalter derav med en farmasøytisk akseptabel syre eller base, og medisinske produkter inneholdende samme er nyttige som spesifikke inhibitorer for typa-13 matriks metalloprotease.
NO20044041A 2002-03-08 2004-09-24 Okso-azabisykliske forbindelser NO20044041L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2002/003240 WO2003076416A1 (en) 2002-03-08 2002-03-08 Oxo azabicyclic compounds
PCT/EP2003/002277 WO2003076417A2 (en) 2002-03-08 2003-03-06 Oxo-azabicyclic compounds

Publications (1)

Publication Number Publication Date
NO20044041L true NO20044041L (no) 2004-10-07

Family

ID=27798761

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044041A NO20044041L (no) 2002-03-08 2004-09-24 Okso-azabisykliske forbindelser

Country Status (25)

Country Link
EP (1) EP1492775A2 (no)
JP (1) JP2005526070A (no)
KR (1) KR20040095270A (no)
CN (1) CN1738806A (no)
AP (1) AP2004003125A0 (no)
AR (1) AR039562A1 (no)
AU (2) AU2002249275A1 (no)
BR (1) BR0308280A (no)
CA (1) CA2478706A1 (no)
CO (1) CO5601020A2 (no)
EA (1) EA200401053A1 (no)
EC (1) ECSP045278A (no)
IL (1) IL163818A0 (no)
IS (1) IS7414A (no)
MA (1) MA27183A1 (no)
MX (1) MXPA04008681A (no)
NO (1) NO20044041L (no)
OA (1) OA12782A (no)
PA (1) PA8568501A1 (no)
PE (1) PE20031018A1 (no)
PL (1) PL372622A1 (no)
SV (1) SV2003001495A (no)
TN (1) TNSN04169A1 (no)
UY (1) UY27700A1 (no)
WO (2) WO2003076416A1 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
WO2004014909A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
AU2003249540A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
MXPA05001603A (es) 2002-08-13 2005-04-25 Warner Lambert Co Derivados monociclicos como inhibidores de metaloproteinasa de matriz.
AU2003253150A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Chromone derivatives as matrix metalloproteinase inhibitors
CA2495293A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
AU2003250466A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
ATE359791T1 (de) 2002-08-13 2007-05-15 Warner Lambert Co Pyrimidin-2,4-dion-derivate als matrix- metalloproteinase-hemmer
AU2003250470A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
WO2004014384A2 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
WO2005016926A1 (en) * 2003-08-19 2005-02-24 Warner-Lambert Company Llc Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors
DE10360835A1 (de) * 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
WO2005105760A1 (en) * 2004-04-30 2005-11-10 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof as an mmp-13 inhibitor
KR20070028536A (ko) * 2004-06-15 2007-03-12 아스트라제네카 아베 항암제로서의 치환된 퀴나졸론
RU2009112397A (ru) 2006-10-05 2010-10-10 Си Ви ТЕРАПЬЮТИКС, ИНК (US) Бициклические азотсодержащие гетероциклические соединения для применения в качестве ингибиторов стеароил соа десатуразы
WO2012052451A1 (en) 2010-10-18 2012-04-26 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
CN103524431B (zh) * 2013-09-24 2016-01-13 西安交通大学 3-苄基-4-喹唑啉酮类化合物及其合成方法和应用
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
WO2017050865A1 (en) 2015-09-23 2017-03-30 Janssen Pharmaceutica Nv Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
WO2017050864A1 (en) 2015-09-23 2017-03-30 Janssen Pharmaceutica Nv New compounds
FR3046793B1 (fr) * 2016-01-14 2018-01-05 Les Laboratoires Servier Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002513394A (ja) * 1996-12-17 2002-05-08 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー 殺菌・殺カビ性のキナゾリノン類
PA8539301A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
PA8539401A1 (es) * 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13

Also Published As

Publication number Publication date
WO2003076417A2 (en) 2003-09-18
PL372622A1 (en) 2005-07-25
JP2005526070A (ja) 2005-09-02
PE20031018A1 (es) 2004-01-09
ECSP045278A (es) 2004-10-26
WO2003076417A3 (en) 2003-11-13
IS7414A (is) 2004-08-19
MA27183A1 (fr) 2005-01-03
EP1492775A2 (en) 2005-01-05
AU2003212307A1 (en) 2003-09-22
CN1738806A (zh) 2006-02-22
CA2478706A1 (en) 2003-09-18
AR039562A1 (es) 2005-02-23
EA200401053A1 (ru) 2005-04-28
KR20040095270A (ko) 2004-11-12
TNSN04169A1 (fr) 2007-03-12
UY27700A1 (es) 2003-10-31
MXPA04008681A (es) 2004-12-06
AU2002249275A1 (en) 2003-09-22
WO2003076416A1 (en) 2003-09-18
SV2003001495A (es) 2003-11-04
IL163818A0 (en) 2005-12-18
PA8568501A1 (es) 2003-12-19
CO5601020A2 (es) 2006-01-31
BR0308280A (pt) 2004-12-28
AP2004003125A0 (en) 2004-09-30
OA12782A (en) 2006-07-10

Similar Documents

Publication Publication Date Title
NO20044041L (no) Okso-azabisykliske forbindelser
NO20066055L (no) Pyridinderivater
DK1585739T3 (da) Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer
NO20055977L (no) Nye benzimidazolderivater
HUP0203385A2 (en) Pyrimidine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
DE69722004D1 (de) Nukleotidanaloga
ATE394379T1 (de) 4-alkoxy-cyclohexan-1-amino-carbonsäureester und verfahren zu ihrer herstellung
DK0752854T3 (da) Pyrimidin- eller triazincarboxylsyrederivater til anvendelse som lægemiddel
AU8811401A (en) Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
DK1233953T3 (da) Nye benzoethiadiazinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende samme
NO20050612L (no) Pyrrolidinderivater som oksytocinantagonister
MX2007006744A (es) Derivados de hidantoina utiles como inhibidores de metaloproteinasa.
NO20063111L (no) Fremgangsmate for fremstilling av tiazolpyrimidiner
EP1027051A4 (en) ANTITHROMBOTIC AGENTS
NO330989B1 (no) Nye piperazinderivater, fremgangsmater for fremstilling av slike og deres anvendelse som syntesemellomprodukter.
ATE258934T1 (de) Azaindol derivate und ihre verwendung als antithrombotische wirkstoffe
UY26251A1 (es) Forma cristalina iii de la n- (4-(5- dimetilaminonaftalen-1- sulfonilamino) fenil) -3 - hidroxi-2, 2- dimetilpropionamida
DE60008430D1 (de) Verbindungen mit antithrombotischer wirkung
EA200100344A2 (ru) Новые циклобутаиндолкарбоксамидные производные, способ их получения и содержащие их фармацевтические композиции
EP1403260A3 (en) Optically active epoxy compounds and processes for their production
NO20052413L (no) Substituted aralkyl derivatives
DE69824410D1 (en) Antithrombosemittel
NO20022690L (no) Nye strukturelle analoger av Vitamin D
EA200200563A1 (ru) Новые соединения инденоиндолона, способ их получения и фармацевтические композиции, их содержащие
FR2839719B1 (fr) Nouveaux composes imidazoliques, leur procede de preparation et leur utilisation a titre de medicaments

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application